Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.
abacavir/lamivudine
ESS30008
NCT00046176
Infection, Human Immunodeficiency Virus I
Phase 3
 
January 2014

Powered by ideaPoint, Inc.